Large intestine

Groundbreaking Early-Age Onset Colorectal Cancer Think Tank Aims to Transform Colorectal Cancer Outcomes

Retrieved on: 
Wednesday, November 29, 2023
Shock, Fatality, CRC, Colorectal cancer, Risk, Vanderbilt-Ingram Cancer Center, Research, Hope, Large intestine, Colonoscopy, Fertility preservation, EAO, Fertility, Cancer, Body image, Patient, Young adult

On December 1, 2023, co-hosted with Vanderbilt-Ingram Cancer Center, Fight CRC will leverage innovation and collaboration by convening leading researchers, medical professionals, and emerging scientists at the Early-age Onset Colorectal Cancer (EAO CRC) Think Tank, with a singular objective: to save young lives from colorectal cancer.

Key Points: 
  • On December 1, 2023, co-hosted with Vanderbilt-Ingram Cancer Center, Fight CRC will leverage innovation and collaboration by convening leading researchers, medical professionals, and emerging scientists at the Early-age Onset Colorectal Cancer (EAO CRC) Think Tank, with a singular objective: to save young lives from colorectal cancer.
  • The EAO CRC Think Tank is an extension of Fight CRC's Path to a Cure initiative , aiming to mobilize colorectal cancer champions nationwide, engage them in the scientific research process, and advocate for colorectal cancer research funding while effectively communicating research findings to the public.
  • In response, Fight CRC has taken proactive measures by establishing the EAO CRC Think Tank and forming strategic partnerships with leading experts in the colorectal cancer medical community.
  • Fight CRC President Anjee Davis states, " We are thrilled to be convening the Early-age Onset Colorectal Cancer Think Tank, uniting the foremost experts in colorectal cancer research.

FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)

Retrieved on: 
Tuesday, November 21, 2023
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Lancet, National Cancer Institute, Jazz Pharmaceuticals, Takeda, CRC, Specialty pharmacy, Anti-VEGF, VEGFR-3, Mortality, Patient, Pharmacy, Large intestine, VEGF, Caregiver, PharMerica, Colorectal cancer, Cancer, Diagnosis, Metastasis, Death, Hospital, Irinotecan, JAMA, Pharmaceutical industry

Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.

Key Points: 
  • Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.
  • Colorectal cancer is the fourth most frequent diagnosed cancer and second leading cause of death in the U.S.
  • Fruquintinib vs Placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicenter, randomized double blind, phase 3 study.
  • Effect of fruquintinib vs Placebo on overall survival in patients with previously treated metastatic colorectal cancer.

LetsGetChecked Enables Health Plans to Increase Medicare Star Quality Ratings by +0.5 Stars

Retrieved on: 
Wednesday, November 15, 2023
Health, Telemedicine, Virtual Medicine, Practice Management, Health Technology, Other Health, Managed Care, General Health, Medicare Advantage, Health Star Rating System, Senior, Patient, Large intestine, CMS, Diabetes, Population health, Medicare, Government, Colorectal cancer, HPV, News, Pharmaceutical industry, Health insurance, Star

LetsGetChecked, a global healthcare solutions company serving top health plans, employers, and government agencies, announced today that their clients achieved higher preventive screening rates and increased Star Ratings for 2022 Centers for Medicare and Medicaid Services (CMS) H-contracts.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company serving top health plans, employers, and government agencies, announced today that their clients achieved higher preventive screening rates and increased Star Ratings for 2022 Centers for Medicare and Medicaid Services (CMS) H-contracts.
  • By using LetsGetChecked to identify and test at-risk member populations for Colorectal Cancer Screening and Diabetes Care, these clients have achieved a Star Rating increase of 0.5 Stars and nearly 1 full Star, respectively.
  • CMS uses a five-star quality rating system to measure Medicare beneficiaries’ experience with their health plans and the healthcare system.
  • “The tangible impact that LetsGetChecked is having on our partners' Star Ratings is truly incredible,” said Addison Giannini, Senior Vice President of Health Plan Sales at LetsGetChecked.

DiaCarta Launches OTC at Home Fecal Occult Blood Test to Complement its ColoScape™ Test

Retrieved on: 
Tuesday, December 5, 2023
Colorectal cancer, Patient, Medicine, Large intestine, FOBT, Blood, US FDA, Cancer, Fecal occult blood, Methylation, Biomarker, OTC, Colonoscopy, Medical imaging

Colorectal cancer is the third most frequent cancer worldwide, emphasizing the critical need for early and effective diagnostic screening methods.

Key Points: 
  • Colorectal cancer is the third most frequent cancer worldwide, emphasizing the critical need for early and effective diagnostic screening methods.
  • DiaCarta is at the forefront of meeting this challenge with the introduction of its advanced iColon FOBT, offering a non-invasive product for early detection of blood in stool at home.
  • The iColon FOBT complements DiaCarta's highly sensitive ColoScape™ Test for qualitative early detection of colorectal cancer-associated mutation and methylation diagnostic biomarkers in circulating blood.
  • "We are excited to introduce our Fecal Occult Blood Test as a significant leap forward in the field of colorectal cancer screening," said Adam (Aiguo) Zhang CEO of DiaCarta.

Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States

Retrieved on: 
Monday, November 20, 2023
Woman, NYSE, DNA, Food, Colorectal cancer, Incidence, American Cancer Society, Ageing, Disease, Mortality, Patient, DSM-IV codes, National Health, Large intestine, Conditional sentence, FDA, National Health Interview Survey, Quest Diagnostics, DGX, Cancer, NGS, Universal, UDX, Health care, Pharmaceutical industry, Medical imaging, Quest, Oncology

CAMBRDIGE, Mass. and SECAUCUS, N.J., Nov. 20, 2023 /PRNewswire/ -- Universal DX ("UDX"), a biotech company on a mission to transform cancer into a curable disease, today announced a strategic collaboration with Quest Diagnostics ("Quest") (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve colorectal cancer screening in the United States – for which more than 110 million people may be eligible.i

Key Points: 
  • Quest's oncology center of excellence in Lewisville, TX, will serve as the single site to support testing for the study.
  • A leader in advanced oncology diagnostics, Quest specializes in testing for inherited genetic disorders and tumor sequencing for colorectal and other cancers.
  • This collaboration will make it more likely that patients in the United States will, over time, have a convenient, quality and accessible option to screen for colorectal cancer."
  • "UDX has created a promising method of screening for colorectal cancer with a simple blood test that includes the ability to detect advanced adenomas.

John Muir Health and Ambience Healthcare Launch End-to-End Epic EHR Integrations with Generative AI

Retrieved on: 
Tuesday, November 14, 2023
Medicine, Pressure, CDI, EHR, SAN, Organization, Pediatrics, ICD-10, Language, CPT, Patient, Electronic health record, Large intestine, John Muir Health, Documentation, History, JMH, AI, Thought, Medical device, Nursing, Entertainment, Hospital, Endocrinology, Ambient, Epic

SAN FRANCISCO, Nov. 14, 2023 /PRNewswire/ -- John Muir Health (JMH) and Ambience Healthcare announced a collaboration today, launching a generative AI platform that is fully integrated with Epic's electronic health record (EHR).

Key Points: 
  • SAN FRANCISCO, Nov. 14, 2023 /PRNewswire/ -- John Muir Health (JMH) and Ambience Healthcare announced a collaboration today, launching a generative AI platform that is fully integrated with Epic's electronic health record (EHR).
  • John Muir Health is well respected as one of the most forward thinking, innovative health systems in the country.
  • Working closely with Ambience and our colleagues at Epic, we're already seeing the technology revolutionize the patient and clinician experience at John Muir Health."
  • Currently, full-time clinicians at JMH are leveraging Ambience to save an average of 1-2 hours per day on EHR documentation.

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Monday, November 13, 2023
Shield, DNA, Colorectal cancer, Neoplasm, CRC, Disease, Mortality, Colonoscopy, Patient, Large intestine, Fear, ECLIPSE, Helmy Eltoukhy, Cancer, Samsung Medical Center, Medical imaging

SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Monday, November 13, 2023
Shield, DNA, Colorectal cancer, Neoplasm, CRC, Disease, Mortality, Colonoscopy, Patient, Large intestine, Fear, ECLIPSE, Helmy Eltoukhy, Cancer, Samsung Medical Center, Medical imaging

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

Johnson & Johnson MedTech Provides Details and Timeline for General Surgery Robot

Retrieved on: 
Tuesday, November 7, 2023
Digital, Science, FDA, Minimally invasive procedure, Robotics, General surgery, University, OR, IDE, Large intestine, ORS, Surgeon, Palm Beach, Ethicon, Freedom, Workflow, Safety, Movement, Johnson & Johnson, Patient, Pharmaceutical industry, Dentistry, Medical device

NEW BRUNSWICK, N.J., Nov. 7, 2023 /PRNewswire/ -- Johnson & Johnson MedTech* today announced plans to submit the OTTAVA robotic surgical system for an investigational device exemption (IDE) application to the U.S. Food & Drug Administration (FDA) in the second half of 2024 to initiate clinical trials.

Key Points: 
  • Drawing on Johnson & Johnson MedTech's more than 135-year legacy of leadership in surgery, OTTAVA reimagines the surgical experience.
  • "Johnson & Johnson was born in surgery with the advent of sterile sutures, and we have since helped surgeons improve care for patients by offering transformative technologies across all types of surgery," said Hani Abouhalka, Company Group Chairman, Robotics & Digital, Johnson & Johnson MedTech.
  • Ethicon instruments on OTTAVA are backed by decades of innovation and market leadership in minimally invasive surgery, providing leading device-to-tissue and user-to-device interactions.
  • The OTTAVA robotic system is under development and is not authorized to be marketed or sold in any market.

EQS-News: Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

Retrieved on: 
Tuesday, November 7, 2023
Colorectal cancer, Health, Physician, Large intestine, BGM, CRC, Partnership, HR, Cancer, Pharmaceutical industry

Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test.

Key Points: 
  • Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test.
  • The partnership was launched in April 2023, when Zöller-Kipper selected ColoAlert®, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program.
  • "Colorectal cancer is the second most lethal form of cancer, and early detection is paramount in enhancing treatment options and survival rates.
  • We are grateful for the successful partnership with Mainz Biomed, their exceptional service and are looking forward to continue our collaboration.”